About Vascular Biogenics
Vascular Biogenics (VBL) is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapies are limited in their ability to adequately treat these serious and oftentimes life-threatening diseases. VBL was founded to create new treatment options that address these unmet medical needs. VBL's clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body's natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.
Missing: Vascular Biogenics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vascular Biogenics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Vascular Biogenics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vascular Biogenics is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Vascular Biogenics Patents
Vascular Biogenics has filed 1 patent.
Clusters of differentiation, Transcription factors, Immunology, Molecular biology, Oncology
Clusters of differentiation, Transcription factors, Immunology, Molecular biology, Oncology
Latest Vascular Biogenics News
Dec 20, 2021
12/20/2021 | 08:00am EST Message : VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, December 20, 2021 - VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it has been selected for €17.5 million of blended funding by the European Innovation Council (EIC) Accelerator. The funding is comprised of a €2.5 million grant and an additional €15 million direct equity investment by the EIC. The EIC Accelerator is a prestigious competitive program of the European Commission, which offers grants combined with equity investments through the EIC Fund. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading expertise, corporates, investors and ecosystem actors. "We are honored to have been selected in this prestigious and competitive program, where only nine percent of companies got funded, with only a small fraction of those in biopharma," said Dror Harats, M.D., Chief Executive Officer of VBL. "In selecting us for this grant and investment, we believe the EIC recognized the value proposition that ofra-vec (VB-111) potentially offers to patients and the high unmet need that exists in ovarian cancer. Ofra-vec offers a novel targeted gene based approach to the way cancer is treated, and if approved, can potentially address some of the key challenges in treating ovarian cancer and establish a new standard of care. We are grateful for the EIC's support and alignment in our collective mission to improve the lives of patients with cancer." The EIC Accelerator's support comes at a pivotal time for VBL. VBL is nearing the completion of enrollment in the ongoing Phase 3 OVAL registration-enabling clinical trial of ofra-vec (VB-111) in ovarian cancer, with the top-line progression free survival (PFS) co-primary endpoint data readout expected in the second half of 2022. The funds from the EIC will be used to support clinical development, Chemistry Manufacturing and Controls (CMC), and pre-commercialization activities. For more information about the EIC Accelerator, refer to https://eic.ec.europa.eu/eic-funding-opportunities/eic-accelerator_en . About VBL Therapeutics Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL's novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that harness the body's innate biological processes to provide unique solutions for significant unmet medical needs. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook. Forward Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding the receipt of the funding, the anticipated use of proceeds, the ofra-vec (VB-111) value proposition and its ability to obtain regulatory approval, timing of completion of enrollment and data readouts for the Oval Phase 3 study and data readouts for the OVAL study, among others. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with establishment of arrangements for implementing the EIC equity investment by Horizon Europe and the timing thereof, as well as risks inherent in the development of pharmaceutical product candidates, including risks associated with conducting research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, and other risks. A further list and description of these risks, uncertainties and other risks can be found in VBL's regulatory filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 20-F for the year ended December 31, 2020, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. CONTACT:
Vascular Biogenics Frequently Asked Questions (FAQ)
When was Vascular Biogenics founded?
Vascular Biogenics was founded in 2000.
Where is Vascular Biogenics's headquarters?
Vascular Biogenics's headquarters is located at 6 Jonathan Netanyahu St., Or Yehuda.
What is Vascular Biogenics's latest funding round?
Vascular Biogenics's latest funding round is IPO.
Who are the investors of Vascular Biogenics?
Investors of Vascular Biogenics include Aurum Ventures, Pitango Venture Capital, GlenRock Israel, Teva Pharmaceuticals and Kadima High Tech.
Who are Vascular Biogenics's competitors?
Competitors of Vascular Biogenics include Dicerna Pharmaceuticals, Oxurion, Alucent Biomedical, Portola Pharmaceuticals, Haemostatix and 14 more.
Compare Vascular Biogenics to Competitors
Martek Biosciences Corporation is a innovator in the development of nutritional products that promote health and wellness through every stage of life.
Kibow Biotech, Inc. develops groundbreaking methods of using probiotics (beneficial bacteria) to bring hope to kidney failure patients worldwide. With the company's scientifically formulated dietary supplements, the company also address metabolic syndrome patients who are at an elevated long-term risk of developing chronic kidney failure (CKF).
Lifetree Biotech is R&R oriented corporation with the goal of researching and developing highly effective, yet safe nutritional properties in herbs and plants. The company's all natural products and dietary supplements for overall health include nutritional programs and diets, using the company's native Korean botanicals. The company's products help prevent and provide relief for various liver and gastro enteric diseases and ailments. The company also manufacture Liver Detoxifying yogurts and all natural herbal supplements that promote balance and overall health to the liver affected by alcohol intake.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.
REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.